Idexx Laboratories (IDXX) Stock News, Dec 2024-Jun 2025

IDEXX Laboratories (NASDAQ: IDXX) has launched the Catalyst Cortisol Test, marking the third expansion of its Catalyst platform in under a year. This innovative test measures real-time cortisol concentrations in dogs to aid in diagnosing Addison's disease and Cushing's syndrome. The test provides point-of-care diagnostic capabilities with accuracy comparable to IDEXX Reference Laboratories. Key features include interpretive guidance through integration with IDEXX Vetlab Station and VetConnect PLUS, and an efficient load-and-go workflow. The test will launch in the U.S. and Canada by July 2025, followed by a global rollout to over 75,000 Catalyst chemistry analyzers starting Q3 2025. This development enhances veterinarians' ability to diagnose and treat life-threatening endocrine disorders during patient visits, particularly benefiting cases of Addison's disease, which is notoriously difficult to diagnose, and Cushing's syndrome, which requires long-term management.

IDEXX Laboratories (NASDAQ: IDXX), a leader in pet healthcare innovation, has announced two upcoming investor events. The company's executives Andrew Emerson (CFO) and Tina Hunt (EVP, Global Strategy and Commercial) will participate in a fireside chat at the Stifel Jaws & Paws Conference on May 28, 2025, from 10:55 am to 11:25 am EDT.

Additionally, IDEXX will host its 2025 Investor Day on August 14, 2025, at its corporate headquarters in Westbrook, Maine. The event will run from approximately 8:00 am to 12:00 pm EDT. Both events will be accessible via live webcast through the company's investor relations website. Institutional investors and analysts interested in attending the Investor Day in person must register by contacting investorrelations@idexx.com.

IDEXX Laboratories (NASDAQ: IDXX) reported Q1 2025 results with revenue of $998 million, showing 4% reported and 5% organic growth. The company's EPS reached $2.96, up 5% reported and 7% on a comparable basis. Key highlights include CAG Diagnostics recurring revenue growth of 3% reported and 4.5% organic, supported by strong IDEXX VetLab consumables performance and over 300 IDEXX inVue Dx placements. IDEXX updated its 2025 guidance, raising revenue expectations to $4,095-$4,210 million and adjusting EPS outlook to $11.93-$12.43. The company launched IDEXX Cancer Dx for early detection of canine lymphoma in North American reference laboratories. Operating margin reached 31.7%, with gross margin expanding by 90 basis points to 62.4%. The company maintains its organic revenue growth projection of 6-9% for 2025.

IDEXX Laboratories (NASDAQ: IDXX), a global leader in pet healthcare innovation, has announced it will release its 2025 first quarter financial results on Thursday, May 1, 2025, before market opening. The company will host an analyst conference call at 8:30 a.m. ET the same day.

Investors and analysts can access the live webcast, prepared remarks transcript, and Q1 2025 Earnings Snapshot through the investor relations section of IDEXX's website. An archived version of the webcast will be available after 1:00 p.m. ET and remain accessible for one year. The conference call can also be accessed via telephone using specific dial-in numbers.

IDEXX Laboratories (NASDAQ: IDXX), a leader in pet healthcare innovation, has announced its participation in two upcoming institutional investor conferences. At the BofA Securities Animal Health Summit on February 27, Mike Erickson (EVP and GM of Point of Care Diagnostics and Telemedicine) and Andrew Emerson (SVP of Corporate and CAG Finance) will engage in a fireside chat from 9:05-9:45 am EST.

Additionally, CEO Jay Mazelsky will present at the 46th Annual Raymond James Institutional Investors Conference on March 3 from 11:35 am-12:05 pm EST. Both presentations will be available via live webcasts through the company's investor relations website (www.idexx.com/investors), with archived versions accessible afterward.

IDEXX Laboratories (NASDAQ: IDXX) reported solid Q4 2024 results with revenue reaching $954 million, up 6% both reported and organic. The growth was driven by Companion Animal Group (CAG) Diagnostics recurring revenue increasing 6% reported and 7% organic.

Q4 earnings per share reached $2.62, rising 13% as reported and 10% on a comparable basis. The company's 2025 outlook projects revenue between $4,055-$4,170 million, representing 4-7% reported growth and 6-9% organic growth. EPS guidance for 2025 is set at $11.74-$12.24, indicating 10-15% reported growth.

The company plans approximately $1.5 billion in share repurchases for 2025, equivalent to ~4% of current market cap. Notable product launches include the IDEXX inVue Dx™ Cellular Analyzer and upcoming IDEXX Cancer Dx™ screening for canine lymphoma, scheduled for March 2025 release in the U.S. and Canada.

IDEXX Laboratories (NASDAQ: IDXX) has announced the launch of IDEXX Cancer Dx™, a groundbreaking diagnostic panel for early detection of lymphoma in dogs. The affordable blood test, priced as low as $15, can be integrated into annual wellness screenings and provides results within 2-3 days.

The test targets the significant market of 20 million dogs at higher risk for cancer in North America, addressing a critical need as 1 in 4 dogs in the U.S. are expected to receive a cancer diagnosis in their lifetime. Lymphoma specifically accounts for nearly 25% of new canine cancer diagnoses.

The panel features high accuracy, simple workflow integration, and includes access to IDEXX Medical Consultants. The test can detect lymphoma before clinical signs appear and will provide B-cell and T-cell phenotype classification for positive results at no additional cost. The service will be available in the U.S. and Canada in late March 2025, with plans to expand the panel over the next three years to cover the majority of canine cancer cases.

IDEXX Laboratories (NASDAQ: IDXX), a global pet healthcare innovation leader, has announced it will release its 2024 fourth quarter and full year financial results on Monday, February 3, 2025, before market opening. The company will host an analyst conference call at 8:30 a.m. ET on the same day.

Investors can access the live webcast, prepared remarks transcript, and Q4 2024 Earnings Snapshot through the company's investor relations website. The webcast recording will be available after 1:00 p.m. ET and remain accessible for one year. For telephone access, participants can dial 1-800-289-0462 or 1-323-794-2442 using passcode 803218.

IDEXX Laboratories (NASDAQ: IDXX) has announced an expansion of its share repurchase program. The company's Board of Directors has authorized the repurchase of 5 million additional shares of common stock, supplementing the existing 1.3 million shares remaining under previous authorizations as of December 3, 2024.

The repurchases can be executed through open market operations, including Rule 10b5-1 plans, or through negotiated transactions at management's discretion. The program has no specified end date and can be suspended or discontinued at any time.